ACTU Actuate Therapeutics
Price Chart
Executive Summary
Actuate Therapeutics announced an expanded preclinical research initiative to evaluate its GSK-3β inhibitor elraglusib in combination with RAS-targeted therapies for difficult-to-treat cancers, particularly RAS-mutant tumors like pancreatic cancer. The company believes the combination may overcome resistance mechanisms and enhance clinical outcomes, with initial data expected in Q2 2026. This is a strategic development effort, not a clinical trial result or regulatory milestone.
Actionable Insight
Traders should monitor for preclinical data readouts in Q2 2026, which could catalyze investor interest if results show enhanced anti-tumor activity. However, given the early stage and lack of clinical data, near-term impact is likely limited.
Key Facts
- Actuate Therapeutics is launching preclinical studies combining elraglusib with RAS inhibitors.
- The goal is to overcome resistance in RAS-driven cancers, including pancreatic cancer, melanoma, and colorectal cancer.
- Initial preclinical data expected in Q2 2026, with additional results in 2H 2026.
- Elraglusib has been administered to over 500 patients and is in a Phase 2 trial for metastatic pancreatic cancer.
- No clinical data or financial figures were disclosed; this is a forward-looking research announcement.
Financial Impact
No immediate financial impact disclosed; potential long-term value if preclinical data support clinical development
Risk Factors
- Preclinical results may not translate to clinical benefit.
- Company faces going concern uncertainty with funding needs beyond Q2 2026.
- Combination strategy is speculative and dependent on third-party RAS inhibitors and collaborators.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251848 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
Press Release
| $1.82 awaiting T+5 | awaiting T+5 | — | $2.02 (+10.99%) |
|
May 11, 2026
4w ago
|
8-K
| $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $2.02 (−30.10%) |
|
May 6, 2026
5w ago
|
DEFA14A
| $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $2.02 (−32.44%) |
|
May 6, 2026
5w ago
|
8-K
| $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $2.02 (−32.44%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $2.02 (−2.88%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $2.02 (−31.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access